CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
Fluviral®biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01153685
NCT01153685Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years.

GlaxoSmithKline·interventional·Posted Jun 30, 2010·Updated Jun 8, 2018

In Brief

A Phase 3 clinical trial evaluating Fluviral® for Influenza. Completed, enrolled 120 participants across 1 site.

Detailed Summary

This study is designed to test the safety and immunogenicity of Fluviral® (2010 - 2011 Season) in adults aged 18 to 60 years and over 60 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 30, 2010
Enrollment StartJul 9, 2010
Primary CompletionJul 31, 2010
TodayJul 2, 2026
Enrollment to primary: 22 daysPosted 16.0 years ago

Interventions

Fluviral®biological

Intramuscular injection, one dose